148 related articles for article (PubMed ID: 26944163)
1. Recombinant human soluble thrombomodulin ameliorates cerebral ischemic injury through a high-mobility group box 1 inhibitory mechanism without hemorrhagic complications in mice.
Nakamura Y; Nakano T; Irie K; Sano K; Tanaka J; Yamashita Y; Satho T; Matsuo K; Fujioka M; Ishikura H; Mishima K
J Neurol Sci; 2016 Mar; 362():278-82. PubMed ID: 26944163
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Treatment with Thrombomodulin Improves Functional Outcomes after Cerebral Ischemia Even if Administration is Delayed.
Nakano T; Nakamura Y; Matsuyama K; Irie K; Yasumura M; Hirata Y; Yamasaki M; Misumi K; Yamashita Y; Myose T; Matsuo K; Sano K; Kamimura H; Ishikura H; Egawa T; Mishima K
Thromb Haemost; 2019 Mar; 119(3):467-478. PubMed ID: 30665239
[TBL] [Abstract][Full Text] [Related]
3. Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Nakano T; Irie K; Hayakawa K; Sano K; Nakamura Y; Tanaka M; Yamashita Y; Satho T; Fujioka M; Muroi C; Matsuo K; Ishikura H; Futagami K; Mishima K
Brain Res; 2015 Oct; 1624():330-335. PubMed ID: 26254727
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats.
Tanaka J; Seki Y; Ishikura H; Tsubota M; Sekiguchi F; Yamaguchi K; Murai A; Umemura T; Kawabata A
Br J Pharmacol; 2013 Nov; 170(6):1233-41. PubMed ID: 24004409
[TBL] [Abstract][Full Text] [Related]
5. Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis.
Tanaka J; Yamaguchi K; Ishikura H; Tsubota M; Sekiguchi F; Seki Y; Tsujiuchi T; Murai A; Umemura T; Kawabata A
Neuropharmacology; 2014 Apr; 79():112-8. PubMed ID: 24262631
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human soluble thrombomodulin protects against brain injury in a CVST rat model, via downregulation of the HMGB1-RAGE axis.
Gu JJ; Chen JB; Zhang JH; Zhang H; Wang SS
Mol Med Rep; 2016 Dec; 14(6):5217-5222. PubMed ID: 27840921
[TBL] [Abstract][Full Text] [Related]
7. Enhanced effect of recombinant human soluble thrombomodulin by ultrasound irradiation in acute liver failure.
Hoshino K; Nakamura Y; Nakano T; Watanabe A; Sheng H; Tachibana K; Ishikura H
Sci Rep; 2020 Feb; 10(1):1742. PubMed ID: 32015385
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism.
Hayakawa K; Mishima K; Irie K; Hazekawa M; Mishima S; Fujioka M; Orito K; Egashira N; Katsurabayashi S; Takasaki K; Iwasaki K; Fujiwara M
Neuropharmacology; 2008 Dec; 55(8):1280-6. PubMed ID: 18634812
[TBL] [Abstract][Full Text] [Related]
9. Emulsified Isoflurane Protects Against Transient Focal Cerebral Ischemia Injury in Rats via the PI3K/Akt Signaling Pathway.
Zhang H; Xiong X; Liu J; Gu L; Li F; Wan Y; Xu S
Anesth Analg; 2016 May; 122(5):1377-84. PubMed ID: 26859875
[TBL] [Abstract][Full Text] [Related]
10. Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model.
Iba T; Nakarai E; Takayama T; Nakajima K; Sasaoka T; Ohno Y
Crit Care; 2009; 13(6):R203. PubMed ID: 20003418
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia.
Nagato M; Okamoto K; Abe Y; Higure A; Yamaguchi K
Crit Care Med; 2009 Jul; 37(7):2181-6. PubMed ID: 19487933
[TBL] [Abstract][Full Text] [Related]
12. Acute hyperglycemia worsens ischemic stroke-induced brain damage via high mobility group box-1 in rats.
Huang J; Liu B; Yang C; Chen H; Eunice D; Yuan Z
Brain Res; 2013 Oct; 1535():148-55. PubMed ID: 24012767
[TBL] [Abstract][Full Text] [Related]
13. Thrombomodulin improved liver injury, coagulopathy, and mortality in an experimental heatstroke model in mice.
Kawasaki T; Okamoto K; Kawasaki C; Sata T
Anesth Analg; 2014 May; 118(5):956-63. PubMed ID: 24781566
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of recombinant thrombomodulin for lung injury after pneumonectomy via inhibition of high-mobility group box 1 in mice.
Takahashi Y; Matsutani N; Dejima H; Nakayama T; Okamura R; Uehara H; Kawamura M
J Trauma Acute Care Surg; 2016 Nov; 81(5):868-875. PubMed ID: 27504958
[TBL] [Abstract][Full Text] [Related]
15. Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates.
Tanaka KA; Fernández JA; Marzec UM; Kelly AB; Mohri M; Griffin JH; Hanson SR; Gruber A
Br J Haematol; 2006 Jan; 132(2):197-203. PubMed ID: 16398653
[TBL] [Abstract][Full Text] [Related]
16. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism.
Hayakawa K; Mishima K; Nozako M; Hazekawa M; Mishima S; Fujioka M; Orito K; Egashira N; Iwasaki K; Fujiwara M
Stroke; 2008 Mar; 39(3):951-8. PubMed ID: 18258837
[TBL] [Abstract][Full Text] [Related]
17. Oxyresveratrol (trans-2,3',4,5'-tetrahydroxystilbene) is neuroprotective and inhibits the apoptotic cell death in transient cerebral ischemia.
Andrabi SA; Spina MG; Lorenz P; Ebmeyer U; Wolf G; Horn TF
Brain Res; 2004 Aug; 1017(1-2):98-107. PubMed ID: 15261105
[TBL] [Abstract][Full Text] [Related]
18. The effect of biodegradable gelatin microspheres on the neuroprotective effects of high mobility group box 1 A box in the postischemic brain.
Jin YC; Kim SW; Cheng F; Shin JH; Park JK; Lee S; Lee JE; Han PL; Lee M; Kim KK; Choi H; Lee JK
Biomaterials; 2011 Jan; 32(3):899-908. PubMed ID: 21035846
[TBL] [Abstract][Full Text] [Related]
19. Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines.
Uzawa A; Mori M; Masuda H; Ohtani R; Uchida T; Kuwabara S
Clin Exp Immunol; 2018 Jul; 193(1):47-54. PubMed ID: 29509323
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator.
Nakano T; Tagashira Y; Egashira S; Morimoto M; Irie K; Hosokawa M; Hayashi T; Egawa T; Hayakawa K; Mishima K
Neuroreport; 2022 May; 33(7):297-303. PubMed ID: 35594440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
